FDA and EMA complete joint GLP-1 receptor agonist pancreatitis signal review: benefit-risk remains favourable
FDA and EMA have completed a joint review of post-marketing safety data for GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) and the risk of acute pancreatitis. Both agencies concluded that while a small absolute increase in pancreatitis risk cannot be excluded, the cardiovascular and metabolic benefits outweigh the risk for approved indications. Labels will be updated to strengthen pancreatitis monitoring guidance without adding new contraindications.
Following increased post-marketing use of GLP-1 receptor agonists (semaglutide ↗, liraglutide ↗, dulaglutide ↗, exenatide) for type 2 diabetes and obesity, FDA and EMA ↗ conducted a joint post-marketing signal review of acute pancreatitis cases reported via FDA MedWatch ↗ and EudraVigilance ↗ between 2016 and 2026.
Key findings: benefit-risk remains favourable
Both agencies concluded that the available evidence does not support a definitive causal link between GLP-1 receptor agonist use and acute pancreatitis. The absolute rate of pancreatitis in GLP-1 users was low (approximately 2–3 cases per 1,000 patient-years), consistent with the background rate in type 2 diabetes populations — who have intrinsically elevated pancreatitis risk due to obesity, hypertriglyceridaemia, and gallstone disease. Cardiovascular and metabolic benefits (LEADER trial for liraglutide, SUSTAIN-6 and SELECT for semaglutide) substantially outweigh the small and uncertain pancreatitis risk for approved indications. The LEADER trial ↗ and SELECT trial ↗ are the key cardiovascular outcomes references.
Label updates: strengthened monitoring guidance
Labels for all GLP-1 receptor agonists will be updated to: (1) strengthen existing pancreatitis warnings — advising discontinuation if pancreatitis is confirmed (not merely suspected); (2) add guidance on monitoring amylase and lipase in patients with prior pancreatitis history, gallbladder disease, or hypertriglyceridaemia; and (3) update the Warnings and Precautions section with clearer risk factor identification. No new contraindications are added. Patients with a history of pancreatitis were already excluded from GLP-1 trials — the update formalises the clinical guidance to avoid GLP-1 use in patients with a prior episode until benefit-risk is carefully assessed. See DailyMed semaglutide label ↗.
Clinical implications for prescribers
For most patients with type 2 diabetes or obesity without prior pancreatitis, GLP-1 receptor agonists remain first-line or preferred agents due to their cardiovascular, weight, and cardiorenal benefits. Prescribers should: conduct baseline history for pancreatitis risk factors (gallstones, hypertriglyceridaemia, alcohol use); counsel patients to report persistent severe abdominal pain promptly; avoid or use with extreme caution in patients with prior pancreatitis; and not routinely monitor amylase/lipase in asymptomatic patients (not validated as predictive of clinical pancreatitis). The ADA Standards of Medical Care ↗ and NICE NG28 diabetes guidelines ↗ remain the primary prescribing frameworks.
FAQ
Does a Boxed Warning mean a drug is being withdrawn?
No. A Boxed Warning ↗ (also called a Black Box Warning) is the FDA's strongest label caution, but the drug remains on the market. It means the agency has determined that a risk is serious enough to require prominent, standardised labelling. The drug continues to be prescribed under appropriate clinical conditions. See the FDA's patient guide to Boxed Warnings ↗.
Where can I read the full updated label?
All current FDA-approved prescribing information is available on DailyMed ↗, maintained by the National Library of Medicine (NLM). Search by drug name to find the most recent label version. Historical label versions are also archived there.